Literature DB >> 15505111

Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Jane W Newburger, Masato Takahashi, Michael A Gerber, Michael H Gewitz, Lloyd Y Tani, Jane C Burns, Stanford T Shulman, Ann F Bolger, Patricia Ferrieri, Robert S Baltimore, Walter R Wilson, Larry M Baddour, Matthew E Levison, Thomas J Pallasch, Donald A Falace, Kathryn A Taubert.   

Abstract

BACKGROUND: Kawasaki disease is an acute self-limited vasculitis of childhood that is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy. Coronary artery aneurysms or ectasia develop in approximately 15% to 25% of untreated children and may lead to ischemic heart disease or sudden death. METHODS AND
RESULTS: A multidisciplinary committee of experts was convened to revise the American Heart Association recommendations for diagnosis, treatment, and long-term management of Kawasaki disease. The writing group proposes a new algorithm to aid clinicians in deciding which children with fever for > or =5 days and < or =4 classic criteria should undergo echocardiography, receive intravenous gamma globulin (IVIG) treatment, or both for Kawasaki disease. The writing group reviews the available data regarding the initial treatment for children with acute Kawasaki disease, as well for those who have persistent or recrudescent fever despite initial therapy with IVIG, including IVIG retreatment and treatment with corticosteroids, tumor necrosis factor-alpha antagonists, and abciximab. Long-term management of patients with Kawasaki disease is tailored to the degree of coronary involvement; recommendations regarding antiplatelet and anticoagulant therapy, physical activity, follow-up assessment, and the appropriate diagnostic procedures to evaluate cardiac disease are classified according to risk strata.
CONCLUSIONS: Recommendations for the initial evaluation, treatment in the acute phase, and long-term management of patients with Kawasaki disease are intended to assist physicians in understanding the range of acceptable approaches for caring for patients with Kawasaki disease. The ultimate decisions for case management must be made by physicians in light of the particular conditions presented by individual patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505111     DOI: 10.1161/01.CIR.0000145143.19711.78

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  572 in total

1.  Coding single-nucleotide polymorphisms of interleukin-1 gene cluster are not associated with Kawasaki disease in the Korean population.

Authors:  Su Kang Kim; Sung Wook Kang; Joo-Ho Chung; Jong Seok Lee; Hyun Kyung Park; Kyung Lim Yoon; Soo Cheol Kim
Journal:  Pediatr Cardiol       Date:  2011-01-30       Impact factor: 1.655

2.  Atypical Kawasaki disease--a clinical challenge.

Authors:  Jonathan Forsey; Luc Mertens
Journal:  Eur J Pediatr       Date:  2011-11-25       Impact factor: 3.183

3.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

4.  Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.

Authors:  Chiea Chuen Khor; Sonia Davila; Willemijn B Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J Wright; Rae S M Yeung; Dennis E K Tan; Kar Seng Sim; Jie Jin Wang; Tien Yin Wong; Junxiong Pang; Paul Mitchell; Rolando Cimaz; Nagib Dahdah; Yiu-Fai Cheung; Guo-Ying Huang; Wanling Yang; In-Sook Park; Jong-Keuk Lee; Jer-Yuarn Wu; Michael Levin; Jane C Burns; David Burgner; Taco W Kuijpers; Martin L Hibberd
Journal:  Nat Genet       Date:  2011-11-13       Impact factor: 38.330

5.  Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan.

Authors:  Daisuke Sudo; Yoshiro Monobe; Mayumi Yashiro; Makiko Naka Mieno; Ritei Uehara; Keiji Tsuchiya; Tomoyoshi Sonobe; Yosikazu Nakamura
Journal:  Eur J Pediatr       Date:  2011-12-10       Impact factor: 3.183

6.  Paediatric rheumatology: Corticosteroids as primary therapy in Kawasaki disease.

Authors:  Rebecca Reindel; Stanford T Shulman
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

7.  Marked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease.

Authors:  Shuang Chen; Youngho Lee; Timothy R Crother; Michael Fishbein; Wenxuan Zhang; Atilla Yilmaz; Kenichi Shimada; Danica J Schulte; Thomas J A Lehman; Prediman K Shah; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-24       Impact factor: 8.311

8.  Primary percutaneous coronary intervention for acute myocardial infarction due to possible sequelae of Kawasaki disease in young adults: a case series.

Authors:  Makoto Ariyoshi; Jun Shiraishi; Masayoshi Kimura; Akihiro Matsui; Mitsuo Takeda; Masayasu Arihara; Masayuki Hyogo; Takatomo Shima; Takashi Okada; Yoshio Kohno; Takahisa Sawada; Hiroaki Matsubara
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

9.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

10.  Mid-term Risk for Subclinical Atherosclerosis and Chronic Myocarditis in Children with Kawasaki Disease and Transient Coronary Abnormalities.

Authors:  Mansingh Parihar; Surjit Singh; Pandiarajan Vignesh; Anju Gupta; Manojkumar Rohit
Journal:  Pediatr Cardiol       Date:  2017-05-17       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.